March 19, 2025 02:48 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Donald Trump, Vladimir Putin discuss ways to end Ukraine war in a two-hour call | 'The controversial ruler died 300 years ago': Uddhav Thackeray questions row over Aurangzeb's tomb | Maha Kumbh showed unity in diversity: PM Modi in Parliament | Think twice before travelling outside US: Indians with H-1B, F-1 visas, green cards warned by immigration attorneys | Mamata Banerjee visits Furfura Sharif, slams Opposition for questioning her intent ahead of 2026 polls | Left, BJP call Mamata's Oxford University invitation fake PhD deja vu, TMC hits back | Violence breaks out in Nagpur over call to remove Aurangzeb's tomb, Fadnavis appeals for peace | Ballet dance between dragon, elephant is the only choice: China after Modi's 'positive' remarks in Lex Fridman podcast | PM Modi meets Tulsi Gabbard, discusses ways to enhance cooperation for tackling terrorism | Trump, Modi are focused on strengthening shared interests of India and US: Tulsi Gabbard

Sun Pharma Q4FY24 PAT grows 34% to Rs 2,655 cr; Rs 5 per share dividend declared

| @indiablooms | May 23, 2024, at 03:40 am

Mumbai: Leading pharmaceutical company Sun Pharmaceutical Industries Ltd announced a consolidated net profit of Rs 2,654.5 crore for the March quarter, a 34 percent increase from the same period last year, media reported.

The consolidated revenue was reported at Rs 11,982.9 crore, a 9 percent rise compared to Rs 10,930.6 crore a year earlier, reported Moneycontrol.

The company's board also declared a final dividend of Rs 5 per equity share for the financial year 2023-24.

Operating EBITDA grew by 8.3 percent to Rs 3,034 crore, up from Rs 2,802 crore in the previous fiscal year.

The EBITDA margin was 25.3 percent, slightly down from 25.6 percent in the same period last year.

For the full year FY24, external API sales were Rs 1,918.7 crore, a decrease of 2.7 percent from the previous year, said the report.

US formulation sales for the full year FY24 were $1,854 million, an increase of 10.1 percent compared to the same period last year.

In Q4 FY24, US formulation sales were $476 million, a growth of 10.9 percent over Q4 of the previous year, making up 33.5 percent of total consolidated sales for the quarter, stated the report.

Global specialty sales reached $271 million, up 11.1 percent year-on-year. Formulation sales in Emerging Markets for the full year FY24 were $1,041 million, up 5.9 percent from the previous year.

Emerging Markets sales for Q4 FY24 were $245 million, growing 10.8 percent from Q4 of the previous year and accounting for 17.2 percent of total consolidated sales for the quarter.

R&D investments for the quarter were Rs 900 crore, compared to Rs 665.7 crore in Q4 FY23.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm
PM Modi on Budget 2024 Jul 23, 2024, at 09:30 pm
Close menu